ERBB2 is altered in 5.44% of malignant solid tumor patients with ERBB2 Mutation present in 2.85% of all malignant solid tumor patients [4].

ERBB2 Mutation is an inclusion criterion in 21 clinical trials for malignant solid tumor, of which 16 are open and 5 are closed. Of the trials that contain ERBB2 Mutation and malignant solid tumor as inclusion criteria, 8 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), and 10 are phase 2 (9 open) [5].

ERBB2 is altered in 3.97% of non-small cell lung carcinoma patients with ERBB2 Mutation present in 3.13% of all non-small cell lung carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 15 clinical trials for non-small cell lung carcinoma, of which 13 are open and 2 are closed. Of the trials that contain ERBB2 Mutation and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 9 are phase 2 (8 open) [5].

ERBB2 is altered in 13.78% of breast carcinoma patients with ERBB2 Mutation present in 3.42% of all breast carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 9 clinical trials for breast carcinoma, of which 6 are open and 3 are closed. Of the trials that contain ERBB2 Mutation and breast carcinoma as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [5].

ERBB2 is altered in 14.87% of urothelial carcinoma patients with ERBB2 Mutation present in 11.54% of all urothelial carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 5 clinical trials for urothelial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (3 open) [5].

ERBB2 is altered in 10.1% of gastric carcinoma patients with ERBB2 Mutation present in 4.46% of all gastric carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ERBB2 is altered in 19.62% of adenocarcinoma of the gastroesophageal junction patients with ERBB2 Mutation present in 4.3% of all adenocarcinoma of the gastroesophageal junction patients [4].

ERBB2 Mutation is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

ERBB2 is altered in 4.69% of colorectal carcinoma patients with ERBB2 Mutation present in 3.33% of all colorectal carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ERBB2 is altered in 3.91% of lung carcinoma patients with ERBB2 Mutation present in 3.1% of all lung carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 3 clinical trials for lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and lung carcinoma as inclusion criteria, 3 are phase 2 (3 open) [5].

ERBB2 is altered in 14.96% of bladder carcinoma patients with ERBB2 Mutation present in 11.71% of all bladder carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 is altered in 9.09% of cervical carcinoma patients with ERBB2 Mutation present in 7.01% of all cervical carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for cervical carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and cervical carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 is altered in 8.03% of malignant uterine neoplasm patients with ERBB2 Mutation present in 5.24% of all malignant uterine neoplasm patients [4].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for malignant uterine neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and malignant uterine neoplasm as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 is altered in 4.32% of lung adenocarcinoma patients with ERBB2 Mutation present in 3.44% of all lung adenocarcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for lung adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and lung adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 is altered in 4.28% of non-squamous non-small cell lung carcinoma patients with ERBB2 Mutation present in 3.41% of all non-squamous non-small cell lung carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 is altered in 3.29% of melanoma patients with ERBB2 Mutation present in 2.97% of all melanoma patients [4].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

ERBB2 is altered in 4.04% of head and neck carcinoma patients with ERBB2 Mutation present in 2.16% of all head and neck carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.14% of pancreatic carcinoma patients with ERBB2 Mutation present in 1.13% of all pancreatic carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 is altered in 8.93% of endometrial carcinoma patients with ERBB2 Mutation present in 5.87% of all endometrial carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ERBB2 is altered in 10.45% of gallbladder carcinoma patients with ERBB2 Mutation present in 5.57% of all gallbladder carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 10.08% of gastric adenocarcinoma patients with ERBB2 Mutation present in 4.39% of all gastric adenocarcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 16.67% of esophageal carcinoma patients with ERBB2 Mutation present in 3.77% of all esophageal carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 4.69% of colorectal adenocarcinoma patients with ERBB2 Mutation present in 3.31% of all colorectal adenocarcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 5.41% of biliary tract carcinoma patients with ERBB2 Mutation present in 3.14% of all biliary tract carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 5.4% of biliary tract neoplasm patients with ERBB2 Mutation present in 3.14% of all biliary tract neoplasm patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for biliary tract neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and biliary tract neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ERBB2 is altered in 6.96% of malignant salivary gland neoplasm patients with ERBB2 Mutation present in 2.92% of all malignant salivary gland neoplasm patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 6.96% of salivary gland carcinoma patients with ERBB2 Mutation present in 2.92% of all salivary gland carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for salivary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and salivary gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 3.6% of oropharyngeal carcinoma patients with ERBB2 Mutation present in 2.52% of all oropharyngeal carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 3.6% of oropharyngeal squamous cell carcinoma patients with ERBB2 Mutation present in 2.52% of all oropharyngeal squamous cell carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 4.07% of bile duct carcinoma patients with ERBB2 Mutation present in 2.5% of all bile duct carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.64% of small cell lung carcinoma patients with ERBB2 Mutation present in 2.45% of all small cell lung carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 4.02% of malignant hepatobiliary neoplasm patients with ERBB2 Mutation present in 2.38% of all malignant hepatobiliary neoplasm patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 4.01% of hepatobiliary neoplasm patients with ERBB2 Mutation present in 2.37% of all hepatobiliary neoplasm patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.81% of head and neck squamous cell carcinoma patients with ERBB2 Mutation present in 1.95% of all head and neck squamous cell carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.42% of lip and oral cavity carcinoma patients with ERBB2 Mutation present in 1.69% of all lip and oral cavity carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.42% of oral cavity carcinoma patients with ERBB2 Mutation present in 1.69% of all oral cavity carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.42% of oral cavity squamous cell carcinoma patients with ERBB2 Mutation present in 1.69% of all oral cavity squamous cell carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 1.71% of malignant glioma patients with ERBB2 Mutation present in 1.53% of all malignant glioma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for malignant glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 3.28% of ovarian carcinoma patients with ERBB2 Mutation present in 1.53% of all ovarian carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.04% of squamous cell lung carcinoma patients with ERBB2 Mutation present in 1.45% of all squamous cell lung carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 1.41% of nasal cavity and paranasal sinus carcinoma patients with ERBB2 Mutation present in 1.41% of all nasal cavity and paranasal sinus carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 4.73% of esophageal squamous cell carcinoma patients with ERBB2 Mutation present in 1.35% of all esophageal squamous cell carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 1.62% of B-cell non-hodgkin lymphoma patients with ERBB2 Mutation present in 1.28% of all B-cell non-hodgkin lymphoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 1.22% of astrocytoma patients with ERBB2 Mutation present in 1.13% of all astrocytoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 2.15% of pancreatic adenocarcinoma patients with ERBB2 Mutation present in 1.12% of all pancreatic adenocarcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ERBB2 is altered in 1.09% of medulloblastoma patients with ERBB2 Mutation present in 1.09% of all medulloblastoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and medulloblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 1.03% of thymic carcinoma patients with ERBB2 Mutation present in 1.03% of all thymic carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 0.98% of rhabdomyosarcoma patients with ERBB2 Mutation present in 0.98% of all rhabdomyosarcoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 0.83% of multiple myeloma patients with ERBB2 Mutation present in 0.83% of all multiple myeloma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 0.91% of soft tissue sarcoma patients with ERBB2 Mutation present in 0.82% of all soft tissue sarcoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.37% of primitive neuroectodermal tumor patients with ERBB2 Mutation present in 0.71% of all primitive neuroectodermal tumor patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 is altered in 0.54% of gastrointestinal stromal tumor patients with ERBB2 Mutation present in 0.54% of all gastrointestinal stromal tumor patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.4% of neuroblastoma patients with ERBB2 Mutation present in 0.53% of all neuroblastoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for ependymoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and ependymoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.35% of laryngeal squamous cell carcinoma patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 is altered in 2.35% of malignant laryngeal neoplasm patients [4].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].